Zobrazeno 1 - 10
of 59
pro vyhledávání: '"R. Mudd"'
Autor:
Tyler J Wellman, Sarah R Mudd, Kelly N Godby, Dustin W Wooten, Jeremy A Ross, Orlando F Bueno, Danielle Wanik, Chaitanya R Divgi, Robert A Comley, Luciano J Costa, Jacob Y Hesterman
Publikováno v:
Translational Oncology, Vol 37, Iss , Pp 101767- (2023)
Background: FDG PET/CT is a tool for assessing response to therapy in various cancers, and may provide an earlier biomarker of clinical response. We developed a novel semi-automated approach for analyzing FDG PET/CT images in patients with multiple m
Externí odkaz:
https://doaj.org/article/c0fa07e75db04630b3f8adad4bf6cb5e
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Amino Acid Sequence of AM-1 VH Region
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4690d3c6ba234726f181827c74d28b66
https://doi.org/10.1158/1535-7163.22505197
https://doi.org/10.1158/1535-7163.22505197
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Table S1: ABT-165 binding affinity; Table S2: ABT-165 in vitro potency; Table S3: Effect of VEGF on anti-DLL4 cellular potency of ABT-165; Table S4: Summary of in vivo efficacy; Table S5: Key safety findings of ABT-487 and ABT-165; Figure S1: Serum c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948fdfba3f05b8a422e19034176fe36d
https://doi.org/10.1158/1535-7163.22505686
https://doi.org/10.1158/1535-7163.22505686
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead. Depatux-m has demonstrated promising clinical activity in glio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::313f2d242d9ae4aea09b4db055c77042
https://doi.org/10.1158/1535-7163.c.6537985.v1
https://doi.org/10.1158/1535-7163.c.6537985.v1
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
This file describes the binding assay details of surface plasmon resonance technology, ligand and receptor binding competition assays, western blot detection of DLL4 protein down-regulation, and the methods to measure total circulating soluble DLL4 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::267ca9367d459176dea46bdd55158c64
https://doi.org/10.1158/1535-7163.22505689.v1
https://doi.org/10.1158/1535-7163.22505689.v1
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a potential drug target in VEGF-independen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2454e519448df5024c51607be68974ce
https://doi.org/10.1158/1535-7163.c.6538150.v1
https://doi.org/10.1158/1535-7163.c.6538150.v1
Autor:
Marc B. Skaddan, Dustin W. Wooten, Kyle C. Wilcox, Martin J. Voorbach, David R. Reuter, Zhaozhong J. Jia, Kelly D. Foster-Duke, Jonathan A. Hickson, Srirajan Vaidyanathan, Aimee D. Reed, Ann E. Tovcimak, Qi Guo, Robert A. Comley, Lance Lee, Sjoerd J. Finnema, Sarah R. Mudd
Publikováno v:
Molecular Imaging and Biology. 24:830-841
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed24a19138aed93e52318682bc74d325
https://doi.org/10.1007/s11307-022-01733-1
https://doi.org/10.1007/s11307-022-01733-1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Min Cheng, Dong Cheng, Wenqing Gao, Fritz G. Buchanan, Jun Guo, Sarah R. Mudd, Chris Tse, Julie L. Wilsbacher, Martin J. Voorbach
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:583-589
Cancer cells are highly dependent on NAD+/NADH produced via the nicotinamide salvage pathway. The rate-limiting enzyme in this pathway is the nicotinamide phosphoribosyltransferase (NAMPT), which we have targeted with novel NAMPT inhibitors. NAMPT in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f63fa176709ddae83703e62c41325a9
https://doi.org/10.1124/jpet.119.259135
https://doi.org/10.1124/jpet.119.259135
Autor:
Susan E. Morgan-Lappe, Wenqing Gao, Enrico L. Digiammarino, Yingchun Li, Surekha S. Akella, Sanjay C. Panchal, Jonathan Hickson, Sarah R. Mudd, Louie Naumovski, Jijie Gu, Ralston Sherry L, Dominic J. Ambrosi, Catherine Zhang, Kelly Foster-Duke, Lucia Eaton, Fang Jiang, Deanna L. Haasch
Publikováno v:
Molecular Cancer Therapeutics. 17:1039-1050
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a potential drug target in VEGF-independen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6f9d4850f963b7e646c9f59b8c47c7
https://doi.org/10.1158/1535-7163.mct-17-0800
https://doi.org/10.1158/1535-7163.mct-17-0800